168 related articles for article (PubMed ID: 17020536)
1. Evidence that the mechanism of antibody-catalysed hydrolysis of arylcarbamates can be determined by the structure of the immunogen used to elicit the catalytic antibody.
Boucher G; Said B; Ostler EL; Resmini M; Brocklehurst K; Gallacher G
Biochem J; 2007 Feb; 401(3):721-6. PubMed ID: 17020536
[TBL] [Abstract][Full Text] [Related]
2. Catalytic antibody activity elicited by active immunisation. Evidence for natural variation involving preferential stabilization of the transition state.
Gallacher G; Jackson CS; Searcey M; Goel R; Mellor GW; Smith CZ; Brocklehurst K
Eur J Biochem; 1993 May; 214(1):197-207. PubMed ID: 8508792
[TBL] [Abstract][Full Text] [Related]
3. An investigation of antibody acyl hydrolysis catalysis using a large set of related haptens.
Odenbaugh AL; Helms ED; Iverson BL
Bioorg Med Chem; 2000 Feb; 8(2):413-26. PubMed ID: 10722164
[TBL] [Abstract][Full Text] [Related]
4. A polyclonal antibody preparation with Michaelian catalytic properties.
Gallacher G; Jackson CS; Searcey M; Badman GT; Goel R; Topham CM; Mellor GW; Brocklehurst K
Biochem J; 1991 Nov; 279 ( Pt 3)(Pt 3):871-81. PubMed ID: 1953683
[TBL] [Abstract][Full Text] [Related]
5. A comparison of flexible and constrained haptens in eliciting antibody catalysts for paraoxon hydrolysis.
Spivak DA; Hoffman TZ; Moore AH; Taylor MJ; Janda KD
Bioorg Med Chem; 1999 Jun; 7(6):1145-50. PubMed ID: 10428386
[TBL] [Abstract][Full Text] [Related]
6. Polyclonal antibody-catalysed amide hydrolysis.
Gallacher G; Searcey M; Jackson CS; Brocklehurst K
Biochem J; 1992 Jun; 284 ( Pt 3)(Pt 3):675-80. PubMed ID: 1622388
[TBL] [Abstract][Full Text] [Related]
7. Molecular recognition by cholesterol esterase of active site ligands: structure-reactivity effects for inhibition by aryl carbamates and subsequent carbamylenzyme turnover.
Feaster SR; Lee K; Baker N; Hui DY; Quinn DM
Biochemistry; 1996 Dec; 35(51):16723-34. PubMed ID: 8988009
[TBL] [Abstract][Full Text] [Related]
8. Similarities of hydrolytic antibodies revealed by their X-ray structures: a review.
Charbonnier JB; Gigant B; Golinelli-Pimpaneau B; Knossow M
Biochimie; 1997 Nov; 79(11):653-60. PubMed ID: 9479447
[TBL] [Abstract][Full Text] [Related]
9. The generation of antibody combining sites containing catalytic residues.
Shokat KM; Schultz PG
Ciba Found Symp; 1991; 159():118-28; discussion 128-34. PubMed ID: 1959444
[TBL] [Abstract][Full Text] [Related]
10. Efficient and selective p-nitrophenyl-ester-hydrolyzing antibodies elicited by a p-nitrobenzyl phosphonate hapten.
Tawfik DS; Lindner AB; Chap R; Eshhar Z; Green BS
Eur J Biochem; 1997 Mar; 244(2):619-26. PubMed ID: 9119032
[TBL] [Abstract][Full Text] [Related]
11. A bait and switch hapten strategy generates catalytic antibodies for phosphodiester hydrolysis.
Wentworth P; Liu Y; Wentworth AD; Fan P; Foley MJ; Janda KD
Proc Natl Acad Sci U S A; 1998 May; 95(11):5971-5. PubMed ID: 9600901
[TBL] [Abstract][Full Text] [Related]
12. Improvement in hydrolytic antibody activity by change in haptenic structure from phosphate to phosphonate with retention of a common leaving-group determinant: evidence for the 'flexibility' hypothesis.
Gul S; Sonkaria S; Pinitglang S; Florez-Alvarez J; Hussain S; Thomas EW; Ostler EL; Gallacher G; Resmini M; Brocklehurst K
Biochem J; 2003 Dec; 376(Pt 3):813-21. PubMed ID: 12946271
[TBL] [Abstract][Full Text] [Related]
13. Characterization of the hydrolytic activity of a polyclonal catalytic antibody preparation by pH-dependence and chemical modification studies: evidence for the involvement of Tyr and Arg side chains as hydrogen-bond donors.
Resmini M; Vigna R; Simms C; Barber NJ; Hagi-Pavli EP; Watts AB; Verma C; Gallacher G; Brocklehurst K
Biochem J; 1997 Aug; 326 ( Pt 1)(Pt 1):279-87. PubMed ID: 9337880
[TBL] [Abstract][Full Text] [Related]
14. Large rate accelerations in antibody catalysis by strategic use of haptenic charge.
Thorn SN; Daniels RG; Auditor MT; Hilvert D
Nature; 1995 Jan; 373(6511):228-30. PubMed ID: 7816136
[TBL] [Abstract][Full Text] [Related]
15. A structural basis for transition-state stabilization in antibody-catalyzed hydrolysis: crystal structures of an abzyme at 1. 8 A resolution.
Kristensen O; Vassylyev DG; Tanaka F; Morikawa K; Fujii I
J Mol Biol; 1998 Aug; 281(3):501-11. PubMed ID: 9698565
[TBL] [Abstract][Full Text] [Related]
16. A rat monoclonal antibody that catalyses the hydrolysis of a nitrophenyl-beta-lactam.
Ostler EL; Dean CJ; Barber N; Valeri M; James S; Resmini M; Boucher G; Romanov N; Brocklehurst K; Gallacher G
Biochem Biophys Res Commun; 2002 Nov; 299(2):273-6. PubMed ID: 12437982
[TBL] [Abstract][Full Text] [Related]
17. A new strategy for the generation of catalytic antibodies.
Shokat KM; Leumann CJ; Sugasawara R; Schultz PG
Nature; 1989 Mar; 338(6212):269-71. PubMed ID: 2922053
[TBL] [Abstract][Full Text] [Related]
18. Augmenting the efficacy of anti-cocaine catalytic antibodies through chimeric hapten design and combinatorial vaccination.
Wenthur CJ; Cai X; Ellis BA; Janda KD
Bioorg Med Chem Lett; 2017 Aug; 27(16):3666-3668. PubMed ID: 28709828
[TBL] [Abstract][Full Text] [Related]
19. Diverse structural solutions to catalysis in a family of antibodies.
Gigant B; Tsumuraya T; Fujii I; Knossow M
Structure; 1999 Nov; 7(11):1385-93. PubMed ID: 10574796
[TBL] [Abstract][Full Text] [Related]
20. pH-dependence and structure-activity relationships in the papain-catalysed hydrolysis of anilides.
Lowe G; Yuthavong Y
Biochem J; 1971 Aug; 124(1):117-22. PubMed ID: 5126467
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
